Lunai Bioworks (LNAI) risk factors, FY2025 10-K

Other

1. 01If serious adverse events or other undesirable side effects or safety concerns attributable to our product candidates occur, they may adversely affect or delay our clinical development and commercialization of some or all of our product candidates

Risks Related to Our Financial Position and Capital Requirements

1. 02We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future
2. 03There is substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing
3. 04We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts
4. 05Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies
5. 06From time to time, we may be subject to legal proceedings, regulatory investigations or disputes, and governmental inquiries that could cause us to incur significant expenses, divert our management’s attention, and materially harm our business, financial condition, and operating results
6. 07Negative publicity has had and may continue to have a negative impact on our business and may have a long-term effect on our relationships with our customers, partners and collaborators

Risks Related to Our Limited Operating History

1. 08Renovaro Cube and BioSymetrics are artificial intelligence (“AI”)-driven healthcare technology companies operating in a rapidly evolving field with a limited operating history, which makes it difficult to evaluate their current business and predict Renovaro Cube’s future performance56% rewritten
2. 09Renovaro Cube and BioSymetrics have a history of net losses and anticipates that they may continue to incur net losses for the foreseeable future64% rewritten
3. 10Renovaro Cube has never generated revenue from its cancer diagnostics AI platform, and does not expect any near-term revenue to offset Renovaro Cube’s ongoing operating expenses, and may never be able to maintain profitability
4. 11Even if we commercially launch Renovaro Cube’s or BioSymetrics’ AI platforms and other products, they may fail to achieve the degree of market acceptance necessary for commercial success29% rewritten
5. 12Renovaro Cube and BioSymetrics may be unable to develop and commercialize new products
6. 13If Renovaro Cube’s or BioSymetrics’ products, or the products of its competitors, directly or indirectly result in harm or injury to patients, Renovaro Cube or BioSymetrics could be subject to significant reputational and liability risks, and its operating results, reputation and business could suffer
7. 14If Renovaro Cube’s or BioSymetrics’ facilities or those of its third-party collaborators become inoperable, their ability to provide its products will be significantly impaired and its business will be harmed27% rewritten
8. 15Renovaro Cube’s and BioSymetrics’ business and results of operations will suffer if it fails to compete effectively30% rewritten
9. 16If Renovaro Cube or BioSymetrics cannot enter new collaborations in a timely manner and on acceptable terms, their efforts to develop and commercialize their products could be delayed or adversely affected56% rewritten
10. 17If Renovaro Cube or BioSymetrics is unable to establish sales and marketing capabilities, they may not be successful in commercializing their productsNew

Risks Related to the Development of Our Product Candidates

1. 18Regulatory and legislative developments on the use of AI and machine learning could adversely affect Renovaro Cube’s or BioSymetrics’ use of such technologies in its platform and other products
2. 19Our novel gene, cell and immunotherapy product candidates and new therapeutic approaches could result in heightened regulatory scrutiny, delays in clinical development or delays in our ability to achieve regulatory approval or commercialization of our product candidates
3. 20Our reliance on third parties, such as university laboratories, contract manufacturing organizations and contract or clinical research organizations, may result in delays in completing, or a failure to complete, non-clinical testing or clinical trials if they fail to perform under our agreements with them
4. 21Changes in healthcare law and implementing regulations, including government restrictions on pricing and reimbursement, as well as healthcare policy, may negatively impact our ability to generate revenues
5. 22We have limited experience in drug development and may not be able to successfully develop any drugs, which would cause us to cease operations
6. 23Clinical trials are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome
7. 24Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control

Risks Related to Our Technology and Intellectual Property

1. 25We have licensed a portion of our intellectual property from our licensors. If we breach any of our license agreements with these licensors, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business
2. 26In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations
3. 27If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected
4. 28Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts
5. 29Issues in the development and use of AI, including machine learning and computer vision, in Renovaro Cube’s AI platform may result in reputational harm or liability39% rewritten
6. 30Failure of, or defects in, Renovaro Cube’s or BioSymetrics’ machine learning and cloud-based computing infrastructure, or increased regulation in the machine learning space, could impair their ability to process data, develop products, or provide test results, and harm their business and results of operations
7. 31Real or perceived errors, failures, or bugs in Renovaro Cube’s or BioSymetrics’ platform and future products could adversely affect their business, results of operations, financial condition, and growth prospects39% rewritten
8. 32Renovaro Cube’s or BioSymetrics’ internal computer systems, or those expected to be used by its third-party research institution collaborators or other contractors or consultants, may fail or suffer security breaches29% rewritten
9. 33If Renovaro Cube or BioSymetrics is unable to protect the confidentiality of its trade secrets, Renovaro Cube’s or BioSymetrics’ business and competitive position would be harmed42% rewritten
10. 34We depend on our information technology and telecommunications systems and those of third parties, the failure or disruption of which could harm our business
11. 35Intellectual property litigation may lead to unfavorable publicity that harms our reputation48% rewritten
12. 36Renovaro Cube’s and BioSymetrics’ use of open-source software could subject our proprietary technology to unwanted open-source license conditions that could negatively impact its business37% rewritten
13. 37The success and growth of Renovaro Cube’s or BioSymetrics’ business depends upon their ability to continuously innovate and develop new products and technologies59% rewritten
14. 38Renovaro Cube’s and BioSymetrics’ AI platform and other related products may become obsolete due to fast growing technological innovations or the entry of competitors with more financial and brand power37% rewritten
15. 39We may not be able to protect our intellectual property rights throughout the world

Risks Related to Employee Matters and Managing Growth

1. 40We have limited corporate infrastructure and may experience difficulties in managing growth
2. 41Management and employee turnover creates uncertainties and could harm our business
3. 42Renovaro Cube and BioSymetrics are highly dependent on their key personnel. If Renovaro Cube or BioSymetrics is not successful in attracting, motivating and retaining highly qualified personnel, they may not be able to successfully implement their business strategy30% rewritten
4. 43If Renovaro Cube or BioSymetrics is unable to scale its operations successfully to support demand for its products following the launch of its platform, its business could suffer47% rewritten
5. 44Renovaro Cube and BioSymetrics will need to grow the size and capabilities of their organizations, and may experience difficulties in managing this growth46% rewritten
6. 45Renovaro Cube’s or BioSymetrics’ employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements23% rewritten

Risks Related To Our Business Operations

1. 46Our business plan may lead to the initiation of one or more product development programs, the discontinuation of one or more development programs, or the execution of one or more transactions that investors do not agree with or that investors do not perceive as favorable to their investment in our Common Stock
2. 47Renovaro Cube’s and BioSymetrics’ business is subject to economic, political, regulatory and other risks associated with international operations22% rewritten
3. 48If we are sued for product or professional liability, we could face substantial liabilities that exceed our resources

Risks Related to our Common Stock

1. 49Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance
2. 50Sales of a substantial number of shares of our Common Stock in the public market could cause our stock price to fall97% rewritten
3. 51We have incurred and will continue to incur increased costs as a result of being a public company and our management expects to devote substantial time to public company compliance programs
4. 52Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of potential gain for our stockholders
5. 53Future sales and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
6. 54Some terms of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management
7. 55Any of the factors listed above may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors, who are responsible for appointing the members of our management
8. 561C. Cybersecurity Risk Management and Strategy
9. 57Our cybersecurity framework is seamlessly integrated broader enterprise risk management strategy, sharing methodologies, reporting mechanisms, and governance structures with other risk domains including legal, compliance, strategic, operational, and financial risks
10. 58To date, we have not identified any cybersecurity threats or past incidents that have had, or are likely to have, a material impact on our company’s operations, business strategy, financial performance, or results of operations55% rewritten
11. 59Our Board is actively involved in our cybersecurity oversight, receiving detailed briefings from internal technology teams or external cybersecurity experts. These sessions are part of the Board’s commitment to continuous learning and staying informed about issues critical to public companies, including cybersecurityNew